Table 1.
Correlation between CRALA expression level and clinicopathological characteristics
| Characteristic | Low CRALA expression | High CRALA expression | P |
|---|---|---|---|
| Age | 0.063 | ||
| <45 | 18 | 34 | |
| ≥45 | 71 | 53 | |
| Tumor size | <0.001 | ||
| T1 | 46 | 13 | |
| ≥T2 | 43 | 74 | |
| Nodal status | |||
| N0 | 56 | 34 | <0.001 |
| ≥ N1 | 33 | 53 | |
| Metastasis | <0.001 | ||
| Yes | 2 | 26 | |
| No | 87 | 61 | |
| Relapse | <0.001 | ||
| Yes | 0 | 10 | |
| No | 89 | 77 | |
| Ki67 | <0.001 | ||
| <14% | 35 | 4 | |
| ≥14% | 54 | 83 | |
| ER | 0.005 | ||
| Negative | 20 | 44 | |
| Positive | 69 | 43 | |
| PR | <0.001 | ||
| Negative | 29 | 62 | |
| Positive | 60 | 25 | |
| HER2 | 0.098 | ||
| Negative | 60 | 55 | |
| Positive | 29 | 32 | |
| TNM stage | 0.001 | ||
| I–II | 76 | 55 | |
| III–IV | 13 | 32 | |
| Molecular subtype | 0.006 | ||
| Basal‐like | 9 | 24 | |
| ERBB2+ | 13 | 20 | |
| Luminal A | 19 | 2 | |
| Luminal B | 48 | 41 | |
Bold text indicates that P < 0.05 was considered significant. CRALA, chemoresistance‐associated long non‐coding RNA; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; TNM, tumor node metastasis.